ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Abstract Background Data from phase 3 trials have demonstrated the efficacy and safety of benralizumab in patients with severe eosinophilic asthma (SEA). We conducted a real-world study examining the baseline characteristics of a large SEA population treated with benralizumab in clinical practice an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Francesco Menzella, Elena Bargagli, Maria Aliani, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Cristiano Caruso, Stefano Centanni, Maria D’Amato, Stefano Del Giacco, Fausto De Michele, Fabiano Di Marco, Elide Anna Pastorello, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Alessandra Vultaggio, Lucia Simoni, Alessandra Ori, Silvia Boarino, Gianfranco Vitiello, Elena Altieri, Giorgio Walter Canonica
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-02-01
coleção:	Respiratory Research
Assuntos:	Benralizumab Exacerbations OCS Real world Severe eosinophilic asthma
Acesso em linha:	https://doi.org/10.1186/s12931-022-01952-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!